Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaundal Urvashi, Tsou Pei-Suen, Sahu Mousumi, Huang Mengqi, Boyden Steven E, Woodford Curtis M, Shriner Daniel, Stenson Emilee, Safran Sarah Ayla, Zhou Yuechen, Talley Taylor A, Gudapati Kaavya, Zhang Xuetao, Kunishita Yosuke, Wang Janet, Shah Ami A, Mayes Maureen D, Doumatey Ayo P, Bentley Amy R, Domsic Robyn, Medsger Thomas A, Ramos Paula S, Silver Richard M, Steen Virginia, Varga John, Hsu Vivien, Saketkoo Lesley Ann, Schiopu Elena, Gordon Jessica K, Criswell Lindsey A, Gladue Heather, Derk Chris, Bernstein Elana J, Bridges S Louis, Shanmugam Victoria, Chung Lorinda, Kafaja Suzanne, Jan Reem, Trojanowski Marcin, Goldberg Avram, Korman Benjamin D, Mullikin James, Thomas James W, Dell'Orso Stefania, Randazzo Davide, Adeyemo Adebowale, Remmers Elaine F, Schwartzberg Pamela L, Aksentijevich Ivona, Rotimi Charles, Wigley Fredrick M, Wang Rong A, Boin Francesco, Khanna Dinesh, Lafyatis Robert, Kastner Daniel L, Gourh Pravitt
Аннотация
METHODS: The study focuses on AA patients with SSc who have more severe vascular phenotypes and poorer outcomes and combines genetics, single-cell RNA sequencing, functional assays, and a mouse model to explore the role of NOTCH4 in SSc vasculopathy and the potential for NOTCH4-directed therapies.
RESULTS: Gene-based testing identified NOTCH4 association at an exome-wide significance with SSc (P = 1.6 × 10-7) and patients with severe vascular disease (P = 3.5 × 10-7). The risk haplotype defined by the missense (c.2824C>T) and promoter (c.-117G>A) variants was enriched in AAs with SSc (11%) vs controls, and the population attributable risk due to this haplotype in AAs with SSc was 2.6%, which was 52-fold higher than in European Americans. The SSc-associated NOTCH4 variants increased NOTCH4 expression and signalling, leading to decreased angiogenesis and increased endothelial-to-mesenchymal transition (EndoMT). Nailfold capillary abnormalities, decreased angiogenesis, and fibrosis of the vascular lumen are commonly seen in SSc. Genetic, chemical, antibody, or Food and Drug Administration-approved drug inhibition of NOTCH4 signalling rescued angiogenesis and returned EndoMT to baseline.
CONCLUSIONS: NOTCH4 variants are associated with SSc pathogenesis and vasculopathy, partly explaining the increased prevalence of SSc in AAs. The study highlights the need for further research and clinical trials in the inhibition of the NOTCH4 pathway as a strategy to treat the vascular and fibrotic manifestations of SSc.